Another GLP-1–Receptor Agonist Improves Glycemic Control in Adolescents with Type 2 Diabetes

Youth-onset type 2 diabetes is associated with rapid development of complications and poor response to metformin monotherapy. Current U.S. FDA-approved options for intensifying glycemic control in such patients include insulin and two subcutaneously injected glucagon-like-peptide-1 (GLP-1)–receptor agonists, liraglutide and exenatide.

In this industry-sponsored, randomized trial, researchers examined another GLP-1–receptor agonist, dulaglutide, in 154 adolescents (age range, 10–17 years) with type 2 diabetes and body-mass index (BMI) >85th percentile. At baseline, mean glycosylated hemoglobin (HbA_1c) was 8.1%; most patients were receiving metformin (with or without insulin), which was continued. Patients received weekly injections of one of …